Form D · Biotechnology

Adimab, Inc.

Lebanon, NH · CIK 0001407166

Offering snapshot reported Nov 29, 2010 · SEC filing

Reported sold
$4M
Offering amount: $4M
Investors reported
10
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 22, 2010
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 29, 2010Initial$3,999,909No comparison10SEC filing
Oct 6, 2009Initial$8,205,751No comparison10SEC filing
Dec 1, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Apr 1, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Sep 17, 2007PaperNot reportedNo comparisonNot reportedSEC filing
Jul 23, 2007PaperNot reportedNo comparisonNot reportedSEC filing
Jul 16, 2007PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-151089

Source: Form D, filed Nov 29, 2010. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Errik B. Anderson Executive
Robert L. Birnbaum Executive
Tillman U. Gerngross Director, Executive
Bill Maris Director
William J. Maris Director
Terrance Mc Guire Director
Michael Ross Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
16 Cavendish Court
Lebanon, NH, 03766